Treatment with anti-interleukin (IL)-17 may play a beneficial role in several subtypes of pustular psoriasis (PP), including generalized pustular psoriasis (GPP), according to findings from 3 case studies published in the journal Cytokine. Known to be a clinically heterogeneous disease entity that comprises a variety of subtypes, PP can be classified into 3 phenotypes: GPP,…
A new study has assessed the impact of a switch from tumor necrosis factor-alpha (TNF-α) inhibition to interleukin (IL)-17 inhibition using brodalumab on symptoms of depression and anxiety in patients with psoriasis, of which generalized pustular psoriasis (GPP) is a form. The study, published in the Journal of Dermatology, found significant improvements in the Psoriasis…
An open-label, multicenter, single-arm, postmarketing trial is set to evaluate the efficacy and safety of spesolimab as well as the impact of immunogenicity on the efficacy, safety, and pharmacokinetics of spesolimab, in patients with generalized pustular psoriasis (GPP) who have already received the drug and still experience recurrent flares. The study, set to start on…
A case has been published of an elderly woman with impetigo herpetiformis, a variant of generalized pustular psoriasis (GPP), concurrent with SARS-CoV-2 infection and undergoing treatment with secukinumab. The case report, published in the Journal of Cutaneous Immunology and Allergy, reported that the patient had a heterogeneous c.28C>T (p.Arg10X) mutation in IL36RN, which is associated…
A recent study published in The Journal of Dermatology has concluded that the p.Pro82Leu variant of the IL36RN gene, discovered in an adult-onset generalized pustular psoriasis (GPP) patient with psoriasis vulgaris, is unlikely to exert a substantial influence on GPP development. “Considering our findings and the fact that the prevalence of GPP is not higher…
The presentation of generalized pustular psoriasis (GPP) is generally heterogeneous, according to a study published in Experimental Dermatology. Although GPP is best known for its recurrent flares of sterile pustules, various systemic complications and comorbidities may also be present. This creates a diagnostic challenge for physicians and can cause significant distress among patients. Existing studies…
The results of a recent study published in the Journal of Investigative Dermatology could have significant implications for the interpretation of IL36RN variants in diagnostic settings, potentially leading to improved management and treatment strategies for patients with generalized pustular psoriasis (GPP). In addition, the study provides new insights into the structural elements that govern IL-36Ra activity,…
Spesolimab (Spevigo®), a humanized monoclonal antibody that specifically blocks the activation of the interleukin-36 receptor, may reduce the risk of generalized pustular psoriasis (GPP) flares by 84% over 48 weeks compared with placebo, Boehringer Ingelheim announced. The pharmaceutical company presented the new late-breaking data from the EFFISAYIL™ 2 trial at the 25th World Congress of…
The American Academy of Dermatology (AAD) announced a collaboration with Boehringer Ingelheim that will connect OM1’s artificial intelligence (AI)-based Patient FinderTM to AAD’s DataDermTM patient registry to improve understanding of generalized pustular psoriasis (GPP) and patients with the condition. The initiative, announced via news release, aims to provide educational resources for the assessment, diagnosis, and…
Promising data have been reported in clinical trials of biologic therapies for patients with generalized pustular psoriasis (GPP) and long-term studies are continuing, but real-life data remain sparse and the efficacy of these agents for the prevention of GPP flares remains to be elucidated, a recent study found. The researchers sought to evaluate the current…
Please login or register first to view this content.
